Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1.
暂无分享,去创建一个
T. Bekaii-Saab | B. Mirakhur | J. Blanc | J. Siveke | T. Macarulla | B. Belanger | L-T. Chen | F. D. de Jong | L.-T. Chen